Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
06/16/2017 06/19/2017 06/20/2017 06/21/2017 06/22/2017 Date
61.16(c) 62.02(c) 62.16(c) 62.41(c) 62.6 Last
951 538 383 837 394 654 331 085 145 418 Volume
+0.51% +1.41% +0.23% +0.40% +0.30% Change
More quotes
Financials (€)
Sales 2017 4 300 M
EBIT 2017 922 M
Net income 2017 587 M
Debt 2017 575 M
Yield 2017 1,92%
Sales 2018 4 520 M
EBIT 2018 1 077 M
Net income 2018 715 M
Debt 2018 68,8 M
Yield 2018 2,05%
P/E ratio 2017 18,95
P/E ratio 2018 15,96
EV / Sales2017 2,96x
EV / Sales2018 2,70x
Capitalization 12 139 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec.The company was founded by Emmanuel Janssen on January 18, 1928 and is... 
Sector
Pharmaceuticals
Calendar
06/22Presentation
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
06/15 UCB : Outcome Capital Announces UCB Pharma Has Acquired Beryllium Discovery
06/14 UCB : New study illustrates large treatment gap in post-fracture care …
06/14 UCB : announces four-year imaging results demonstrating low disease progression ..
06/14 UCB : Results from CRIB study on CIMZIA® (certolizumab pegol) demonstrate minima..
06/14 UCB : New UCB data demonstrates scientific innovation for immunology patients wi..
06/11 UCB : Research!America - Briefing
06/09 UCB : Research!America - Briefing
06/08 UCB : Transparency notification BlackRock, Inc.
06/02 UCB : Transparency notification
06/02 UCB : Transparency notifications BlackRock, Inc.
More news
Sector news : Pharmaceuticals - NEC
08:48aDJR. JOHNSON : Missouri Sues Drug Firms Over Opioid Marketing -- WSJ
06/21 Healthcare stocks rally as Senate set to unveil bill
06/21DJJOHNSON & JOHNSON : J&J Seeking Dismissal of Talc Lawsuits in Missouri
06/21DJR. JOHNSON : Missouri Files Its Own Suit Against Opioid-Painkiller Producers -- ..
06/21DJJOHNSON & JOHNSON : Missouri Files Its Own Suit Against Opioid-Painkiller Produc..
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on UCB 
04/07There is still some upside potential
More Strategies
Latest Tweets
06/19“You can turn on the TV and see a UCB person… but it still doesn’t feel like ..
4
06/19Our UCB interview & performance starts now live on
2
06/19Don't miss our special UCB interview & performance live on
3
06/14UCB : New study illustrates large treatment gap in post-fracture care &he.. 
06/14BRIEF-UCB SA says results from CRIB study on Cimzia show minimal to no placen.. 
More tweets
Qtime:44
News from SeekingAlpha
05/22 Amgen's and UCB's romosozumab successful in late-stage osteoporosis study but..
03/21 UCB Needs Clinical Success To Drive Upside
02/24 UCB S.A. 2016 Q4 - Results - Earnings Call Slides
02/24 UCB's (UCBJF) CEO Jean-Christophe Tellier on Q4 2016 Results - Earnings Call ..
02/23 UCB S.A. reports FY results
Advertisement
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Average target price 66,9 €
Spread / Average Target 7,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB2.46%13 456
JOHNSON & JOHNSON16.50%361 566
ROCHE HOLDING LTD.8.81%224 305
NOVARTIS7.69%214 091
PFIZER4.31%199 854
MERCK AND COMPANY11.19%176 500
More Results